Pfizer’s Bococizumab Yields Positive Results in Phase 3

Pfizer’s bococizumab soared in a second Phase 3 study, meeting its co-primary endpoints of reducing low-density lipoprotein cholesterol at 12 weeks compared with placebo.

The SPIRE-AI study assessed the PCSK9 inhibitor in 299 patients with hyperlipidemia or mixed dyslipidemia receiving statin therapy.  SPIRE-AI is the second of six studies evaluating the candidate’s lipid-lowering capabilities.

Bococizumab is not approved in any country.